The NeurologyLive Expert Authors page highlights all the content published on our site that was authored by subject matter experts, including clinicians, neurologists, neurology specialists, advanced practice providers, and more.
Are you a subject matter expert who's interested in submitting to NeurologyLive? Contact our editorial director, Matt Hoffman, by email: mhoffman@mjhlifesciences.com.
Therapeutic Potential of IGF-1 and MECP2 in Rett Syndrome
April 16th 2023Research that is already underway will be necessary to confirm the safety and efficacy of this class of Rett syndrome therapies, and targeting IGF-1 may be a possibility for treating additional neurological disorders beyond Rett.
Therapeutics Aim at Modifying Alzheimer Disease
April 16th 2023Disease-modifying agents will require early detection, including comprehensive evaluation of disease severity and alternative or confounding diagnoses. When the long-awaited moment arrives, when disease-modifying therapies finally are available for ADRDs…will we be ready?
An Overview of Therapeutic Options for Amyotrophic Lateral Sclerosis
March 4th 2023With an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Aβ Protofibril Elimination in Alzheimer Disease
January 21st 2023One model of AD suggests that Aβ pathophysiology triggers downstream molecular pathways, including tauopathy, which lead to cortical neurodegeneration, and cognitive decline is further attributed to the associated neurocortical Aβ plaques.
The Relationship Between Epstein-Barr Virus and Multiple Sclerosis
November 23rd 2022The paradigm-shifting evidence of the link between MS and EBV does not exist in isolation. In fact, the relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades.
Use of Nanoparticles to Combat Neurodegenerative Disease
November 10th 2022Available neurodegenerative disease treatments are generally unsafe and ineffective at penetrating the blood-brain barrier, though the use of nanoparticles can provide improved penetration and exert a neuroprotective effect.
Advocacy and Empowerment: Finding Your Advocacy Community
November 9th 2022The Palatucci Advocacy Leadership Forum, or PALF, sponsored by the American Academy of Neurology, gives neurologists and trainees tools to successfully advocate for their ideas and develop their identity as physician advocates.
Advocacy in Neurology: A Tool to Serve and Find Fulfillment
November 7th 2022Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.
Shifting the Paradigm: Earlier Use of On-Demand Therapy for Treating OFF Time in Parkinson Disease
August 15th 2022Despite the availability of medications to relieve OFF episodes in Parkinson disease, widespread adoption of on-demand therapies has been less-than-ideal, marking the need to shift the treatment paradigm in PD.
Achieving Greater Diversity in Dementia Research: A Call to Action
June 20th 2022Achieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.
New Treatments in Migraine: An In-Depth Review
June 16th 2022Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.
Endoplasmic Reticulum and/or Mitochondrial-Dependent Neuronal Degeneration in ALS
June 14th 2022Given the importance of mitochondrial and endoplasmic reticulum function in ALS, the disruption of intracellular mitochondria-endoplasmic reticulum contacts presents yet another avenue for neuronal degeneration—perhaps the primary point of underlying dysfunction.
The Aducanumab Saga and the Future of Antiamyloid Monoclonal Antibodies
June 13th 2022The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Pressing Gaps in Care Exist for Patients With Parkinson Disease
April 23rd 2022The pandemic has highlighted several large gaps in care that have created challenges for individuals with Parkinson disease, including a framework for addressing mental health and loneliness, and proper care for women with PD.
COVID-19 Shutdowns and the Disruption to Deep Brain Stimulation Treatment
April 22nd 2022While shutdowns disrupted care for all patients with Parkinson disease, hospitals were forced to postpone elective procedures such as the initial DBS device implantation and implantable pulse generator replacements.